Barinthus Biotherapeutics plc
BRNS
$0.74
-$0.02-2.49%
NASDAQ
| 06/30/2026 | 03/31/2026 | ||||
|---|---|---|---|---|---|
| Revenue | -- | -- | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | -- | -- | |||
| Cost of Revenue | 1,347.60% | -27.54% | |||
| Gross Profit | -1,347.60% | 27.54% | |||
| SG&A Expenses | 195.75% | 58.47% | |||
| Depreciation & Amortization | -- | -- | |||
| Other Operating Expenses | 89.13% | 89.40% | |||
| Total Operating Expenses | 88.85% | 18.32% | |||
| Operating Income | -88.85% | -18.32% | |||
| Income Before Tax | -91.39% | 50.27% | |||
| Income Tax Expenses | -43.75% | 71.93% | |||
| Earnings from Continuing Operations | -91.53% | 50.16% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | 533.33% | -76.92% | |||
| Net Income | -91.29% | 50.13% | |||
| EBIT | -88.85% | -18.32% | |||
| EBITDA | -93.62% | -20.71% | |||
| EPS Basic | -91.29% | 50.15% | |||
| Normalized Basic EPS | -95.15% | -17.86% | |||
| EPS Diluted | -85.71% | 48.45% | |||
| Normalized Diluted EPS | -95.15% | -17.86% | |||
| Average Basic Shares Outstanding | 0.00% | 0.03% | |||
| Average Diluted Shares Outstanding | 0.00% | 0.03% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||